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Mild cognitive impairment (MCI) is a common feature in Parkinson’s Disease (PD),
even at the time of diagnosis. Some levels of heterogeneity in nature and severity
of cognitive impairment and risk of conversion to Parkinson’s Disease Dementia
(PDD) exist. This brief overview summarized the current understanding of MCI in
PD, by considering the following major points: historical development of the clinical
entity, evaluation, epidemiology, predictors and outcomes, neuroimaging findings,
pathophysiology, treatment, and pharmacological and non-pharmacological intervention.
MCI in PD represents a concept in evolution and plays a pivotal role in advancing
our understanding of the disease mechanisms, with the ultimate goal of building
effective strategies to prevent conversion into PDD. Challenges for future research are
also discussed.
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INTRODUCTION
From its first conceptualization, mild cognitive impairment (MCI) has been recognized as
a transitional state between normal cognition and overt dementia, especially of Alzheimer
type (Petersen et al., 1999). Then, the Recommendations from the National Institute on
Aging-Alzheimer’s Association workgroup pointed out the symptomatic pre-dementia phase of
Alzheimer’s Disease (AD; i.e., MCI due to AD) by depicting a set of criteria with increasing
levels of certainty, depending on the presence and nature of biomarker findings beyond cognitive
impairment (Albert et al., 2011). More recently, the classification of the DSM 5 recognized
the clinical entity of Minor Neurocognitive Disorder (NCD) for different neurodegenerative
disorders including Parkinson’s Disease (PD), in order to establish a primary level of
cognitive impairment in comparison with Major NCD, reporting a more severe deterioration
(Regier et al., 2013).
In the last years, there has been an increasing emphasis on the identification of MCI in PD
(PD-MCI). Interestingly, PD conception itself has progressively changed over time, moving from
a ‘‘motor disease’’ to a ‘‘complex brain disease.’’ This turnover was supported by the presence of
well-documented non-motor disorders, particularly cognitive deficits.
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In order to provide clinicians and researchers a global
perspective on the construct of MCI in PD, our review represents
a brief summary of update knowledge on PD-MCI encompassing
the following major points: historical development of the clinical
entity, evaluation, epidemiology, predictors and outcomes,
neuroimaging findings, pathophysiology, treatment, and
pharmacological and non-pharmacological intervention.
PD-MCI EVALUATION
The heterogeneous evaluation to ascertain PD-MCI has
led to substantial variation in the percentage of patients
classified. To address this issue, the Movement Disorder
Society (MDS) proposed standardized diagnostic criteria
for PD-MCI (Litvan et al., 2012; Geurtsen et al., 2014).
First, the presence of MCI in an established PD—diagnosed
based on UK PD Brain Bank Criteria—reflecting a gradual
decline as reported by either the patient or informant, not
sufficient to significantly interfere with patients’ functional
independance. Second, cognitive deficits are reported on a formal
neuropsychological examination as performances approximately
1–2 standard deviations below appropriate norms. MDS
diagnostic criteria encompassed two operationalization levels
for neuropsychological examination. Level I criteria are
based on impairment in a global cognitive test validated
for use in PD or in a brief neuropsychological assessment
(i.e., less than two tests for each of cognitive domains assessed,
i.e., attention/working memory, executive function, memory,
visuospatial skills, and language). Level II criteria, based on
a comprehensive neuropsychological evaluation, require an
impairment on at least two neuropsychological tests, represented
by either two impaired tests in one cognitive domain or
one impaired test in two different cognitive domains. The
Level II criteria allow MCI subtyping (i.e., single domain or
multiple domain).
Since 2012, an MDS Study Group was created for the
validation of MCI in PD with the ultimate goal of comparing
the two assessment levels in predicting PD-MCI conversion
into Parkinson’s Disease Dementia (PDD). The study of
Goldman et al. (2013) documented that MDS Task Force
Level II recommendations provide a suitable framework
for creating an efficient neuropsychological battery able to
detect MCI in PD. This finding was then corroborated by
other investigations (Stefanova et al., 2015; Bezdicek et al.,
2017) while the utility of MDS Level I diagnostic criteria
for MCI has been under debate for a long period (Szeto
et al., 2015; Uysal-Cantürk et al., 2018). Lastly, the MDS
Study group (Hoogland et al., 2019) concluded that Level
I PD-MCI criteria classification also confers an independent
contribution to the hazard of PDD while taking age, sex,
education, motor sign severity, and depression into account,
supporting its feasibility for neuropsychological diagnosis.
With MDS Level II criteria, multiple domain impairment
was more frequent than single-domain impairment, with
predominant executive functioning, memory, and visuospatial
deficits (Litvan et al., 2012; Cammisuli and Crowe, 2018).
Furthermore, PD–Cognitive Rating Scale and Mattis Dementia
Rating Scale-2 have been identified as suitable tests for
distinguishing PD-MCI patients from cognitively normal PD
patients (Koevoets et al., 2018).
Until now, biomarkers are not part of PD-MCI definition
(Litvan et al., 2012). However, low levels of amyloid-β 42
(Aβ42) in cerebrospinal fluid (CFS) are associated with increased
risk to develop cognitive impairment in PD (Alves et al.,
2014). Most recently, a study observed a decreased network
involving alpha activity over the occipital lobe, and increased
network involving beta activity over the frontal lobe associated
with a reduction over the parietal lobe, an increased network
involving theta and delta activity over the frontal lobe, and a
reduction of networks involving theta and delta activity in the
parietal lobe. Furthermore, quantitative electroencephalography
(EEG) analysis showed a significant decrease of alpha power
spectral density (PSD) over the occipital regions and an
increase of delta PSD over the left temporal region in PD-MCI
as compared to patients with normal cognition (Mostile
et al., 2019). Moreover, the correlation between PD-MCI and
Rapid Eye Movement Sleep Behavior Disorder (Zhang et al.,
2016) or olfactory dysfunction (Kawasaki et al., 2016) is
widely confirmed. The relation between cognitive impairment
and the presence of tau proteins in PD-MCI is currently
under debate. Some studies suggest no association between
them whereas high levels of T-tau and P-tau were shown
to be associated with cognitive impairment in PD patients
(Yu et al., 2014).
EPIDEMIOLOGY, PREDICTORS,
AND OUTCOME
Approximately 30%–40% of PD patients show cognitive
impairment (Wojtala et al., 2019). Prevalence of PD-MCI
may be an artifact of application methods of the criteria
used for diagnosis (e.g., cut-offs of neuropsychological
test scores, assessment levels, clinical settings, etc.). In the
article depicting PD-MCI diagnostic criteria and assessment
levels (Litvan et al., 2012), the mean prevalence of such a
category was estimated at 27%. By considering cut-off scores
of neurocognitive testing, Yarnall et al. (2014) reported a
variable mean prevalence of PD-MCI of 65.8% (at 1 standard
deviation), 42.5% (at 1.5 standard deviation) and 22.4% (at
2 standard deviation) below the normative values. Then,
two cross-sectional studies estimated the prevalence of
PD-MCI at 33% and 64%, respectively (Marras et al., 2013;
Lawrence et al., 2016). In the Parkinson’s Disease Cognitive
impairment Study (PACOS; Baschi et al., 2018; Monastero
et al., 2018), including 659 non-demented PD patients, the
prevalence of PD-MCI was 39.6% in the whole sample.
Few longitudinal studies have assessed the incidence of
PD-MCI according to the MDS Level II criteria (Broeders
et al., 2013; Domellöf et al., 2015; Santangelo et al., 2015;
Cholerton et al., 2018). The most recent study by Nicoletti
et al. (2019) reported an incidence rate of PD-MCI of
184.0/1000 Pyar.
PD-MCI is associated with increasing age, male gender,
and lower level of education, and its development seems to
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be influenced by a number of non-motor features, including
sleep behavior disorders, severity of daytime sleepiness, and
autonomic impairment as well as depression and anxiety
(Palavra et al., 2013). Motor disease severity, akinetic rigid
phenotype (Wojtala et al., 2019), and comorbidity with
metabolic syndrome (Peng et al., 2018) seem to be associated
with cognitive deterioration in PD, too. Conversely, higher
levels of physical exercise, including strength, aerobic, and
balance training in midlife, are associated with a lower risk
of PD, and patients who remain physically active report
greater quality of life and lower rates of falls and fractures
(Mantri et al., 2018). By contrast, physical inactivity is a
contributing factor in many diseases, including metabolic
syndrome, characterized by inflammation and oxidative stress,
thought also as presumed pathogenetic mechanisms of PD
(LaHue et al., 2016).
Although it is difficult to compare among studies, a
considerable amount of PD-MCI patients progress to PDD
(19%–62%) when they are followed from 2 to 5 years after
diagnosis (Wood et al., 2016). Recently, conversion rates from
PD-MCI to PDD have been reported by one study more precisely
as from 39% to 50% at a 5-years follow-up (Pedersen et al., 2017).
Moreover, findings from longitudinal studies also documented
significant rates of reversion to normal cognition of PD-MCI
patients ranging from 11% to 27.8% at the same follow-up period
(Domellöf et al., 2015; Weil et al., 2018).
NEUROIMAGING FINDINGS AND
PATHOPHYSIOLOGY
The pattern of PD-MCI is characterized by cortical atrophy,
mainly involving the right anterior temporal, left prefrontal
and insular, and right parietal and occipital areas (Melzer
et al., 2013). Atrophy proceeds to subcortical areas as well in
the course of the pathology (Melzer et al., 2013). Diffusion
tensor imaging (DTI) and diffusion-weighted imaging magnetic
resonance imaging (MRI) techniques were used to investigate
such brain regions. A recent study (Xiuqin et al., 2018)
aiming at identifying the specific neuroanatomical alterations
in early drug-naive PD-MCI patients by using voxel-based
morphometry (VBM) showed that they exhibit atrophy in the
right entorhinal cortex (ENT) in comparison to PD patients
with normal cognition. A resting-state functional MRI study
(Wang et al., 2018) documented hyperactivity—reflecting a
compensatory mechanism—in the opercular part of right
inferior frontal gyrus and hypoactivity—associated with
cognitive decline—in the occipital areas in early PD with
MCI. Studies carried out by positron emission tomography
with f18-fluorodeoxyglucose (FDG-PET) showed a reduced
metabolism of posterior brain cortical areas of PD-MCI
patients. An investigation using the single-photon emission
computed tomography imaging of dopamine transporters
(DAT-SPECT) revealed that dopamine uptake reduction on
caudate nucleus may better predict cognitive decline in PD
when this technique is associated to other variables, such
as patients’ age and CSF biomarkers (Schrag et al., 2017).
A very recent study with a multi delay multiparametric
arterial spin labeling investigated cerebral perfusion including
cerebral blood flow (CBF) and arterial transit time (ATT)
in PD-MCI patients using a voxel-based brain analysis and
showed that ATT may be a more sensitive marker than
CBF, by highlighting the potential role of thalamus and
inferior parietal region in detecting MCI on early stage of PD
(Suo et al., 2019).
Moreover, some studies suggest heterogeneous underlying
neuropathology characterized by the presence of Lewy bodies in
neocortical and/or limbic areas of PD-MCI patients (Jellinger,
2010). Recent studies show that white matter abnormalities,
as revealed by DTI, precede for gray matter atrophy in
non-demented PD, although the role of such degeneration
in white matter in cognitive decline in PD is still debated
(Mak et al., 2015).
Finally, there is increasing evidence linking small vessel
disease (SVD) to motor and cognitive symptoms in PD. SVD,
including white matter hyperintensities, lacunes, perivascular
spaces, and microbleeds, is associated to functional and cognitive
decline in PD patients (Foo and Kandiah, 2016). However, the
lack of uniform criteria and standardized imaging techniques
currently hamper research progress exploring the relationship
between cerebrovascular disease and PD.
PHARMACOLOGICAL AND
NON-PHARMACOLOGICAL TREATMENT
Currently, there are no effective drugs for improving cognition
in PD-MCI. A recent study has hypothesized that treatment
with atomoxetine would improve executive functioning in
patients with PD-MCI, including executive control, set-shifting,
and working memory (Hinson et al., 2017). Cholinergic
degeneration could contribute to gait impairments, cognitive
impairment, psychosis, and REM-sleep disturbances, and
rivastigmine may be particularly useful for cognitive dysfunction
also in PD patients (Perez-Lloret et al., 2016). Novel trials
are nowadays implemented to test inhibitor of non-receptor
tyrosine kinase Abelson (c-Abl kinase) activity, among which
nilotinib seems to have success (phase 1 clinical trial on animal
models; Lindholm et al., 2016). Moreover, prasinezumab
(PRX002)—an anti-α-synuclein monoclonal antibody—is
being used as a first-in-human phase 1 clinical trial (Schenk
et al., 2017). A very recent investigation has shown that the
use of cholinesterase inhibitors or memantine—a blocking of
N-Methyl-D-aspartate (NMDA) receptors—may play a role in
improving cognitive and motor function as well as behavioral
symptoms in PD patients (Meng et al., 2019). Furthermore,
the gut micriobiome claimed as an etiopathogenetic factor
would suggest a novel target in PD pharmacotherapy
(Mulroy and Bhatia, 2019).
The risk of developing PD appeared to be inversely associated
with physical activity (PA) practiced during life (Sutoo and
Akiyama, 2003; Chen et al., 2005; Xu et al., 2010; Alonso-Frech
et al., 2011). Moderate-to-vigorous exercise in early adult life
was associated with a highly significant 60% lower PD risk in
men and a lower risk reduction in women (Chen et al., 2005;
Ahlskog, 2011). In addition, the major positive adaptation of
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PA is related to increased insulin/IGF sensitivity and ketone
utilization; increased expression of BDNF, FGF2, and VEGF with
improved bioenergetics; and enhanced neuroplasticity (Mattson,
2014). It has been demonstrated that aerobic exercise, stretching,
and balance training improve motor functions in PD patients
(States et al., 2011). In particular, PA enables PD patients to
maintain their psychomotor learning abilities (Paillard et al.,
2015). The Parkinson Progression Markers Initiative (PPMI)
documented that only 47% (in a total of 383 PD patients)
reported activity consistent with the American Heart Association
(AHA) Recommendation (i.e., 150 min of moderate or 75 min
of vigorous PA weekly performed; Marek et al., 2018). PA,
such as dance and cognitive exercise associated with motor
training, has been shown to be effective in improving global
cognitive function, processing speed, sustained attention, and
mental flexibility in PD patients of mild/moderate stage, with
a 6-years clinical diagnosis of disease (da Silva et al., 2018).
Specifically, treadmill training performed three times a week
for about 60 min in a total of 24 weeks produced a larger
improvement in cognition (da Silva et al., 2018). PD patients
performing progressive resistance training improved cardiac
sympathetic modulation, as measured by heart rate variability
and blood pressure response, too (Kanegusuku et al., 2017).
Available knowledge on the mechanisms involved in the
protective role of PA for PD patients resulted from animal
models. In particular, PA reduces the alteration of the
dopaminergic neurons in the substantia nigra and contributes
towards reconstituting the basal ganglia functions involved in
motor commands (Speelman et al., 2011). Such action is related
to an increased concentration of brain-derived neurotrophic
factor (Wu et al., 2011). Aerobic exercise for PD rats on sessions
lasting from 20 to 60 min, performed 5 days a week for 4 weeks,
can restore the expression of the glial fibrillary acidic protein in
the dorsal striatum (Dutra et al., 2012). Furthermore, regular and
continuous aerobic training of rats over a period of 18 months
also had a neuroprotective effect on the cerebellum (Larsen
et al., 2000), which is centrally involved in movement and
balance control.
Evidences from literature have further supported the
potential role played by cognitive training (CT) and transcranial
stimulation as complementary strategies to pharmacological
treatment in PD-MCI. A randomized controlled trial
including PD-MCI patients (Petrelli et al., 2014) showed
specific effects of cognitive multicomponent structured
(i.e., NeuroVitalis) and non-structured (i.e., ‘‘Mentally
Fit’’) interventions on short-term and working memory
and on depression, respectively. Repeated sessions of
anodal transcranial direct current stimulation (tDCS)
on PD-MCI patients lead to a reduction of depressive
symptoms and to increased performance in motor abilities
and cognitive functions (especially in global cognition and
verbal fluency), with stable effects at 3-months follow-up
(Manenti et al., 2016). Remarkably, it has been shown
that tDCS over the medial prefrontal cortex enhances
cognitive Theory of Mind ability, suggesting this technique
as useful to improve the social cognition of PD-MCI
patients, too (Adenzato et al., 2019). A pilot study using
a composite strategy of computer-based CT (i.e., 30 min,
4 days a week for 4 weeks) and tDCS over dorsolateral
prefrontal cortex administered during executive tasks
showed that tDCS extend the effect of CT on learning tests
(Biundo et al., 2015).
DISCUSSION
PD-MCI is a syndrome defined by clinical, cognitive, and
functional criteria. PD patients may present with non-motor
features that are associated with increased disability and
reduced quality of life and their relation with dopaminergic
treatment needs to be further explored (Wishart and
Macphee, 2011). A significant heterogeneity exists with
respect to cognitive profiles found in PD-MCI patients
that are likely predictive of distinct outcomes regarding
the occurrence of PDD, with single domain (amnestic)
MCI patients at higher risk (Hoogland et al., 2018).
Complete neuropsychological testing of Level II criteria
represents the gold standard for the diagnosis of PD-MCI,
even though additional research is needed to identify a
neuropsychological test battery for multisite international
protocols that is sensitive to cognitive decline and responsive to
therapeutic interventions.
To date, the validity of MCI in PD as a clinical entity is
sustained by converging neuropsychological data, whereas
research on biomarkers should be improved, even if emerging
evidences from neuroimaging studies in differentiating
neuroanatomical features of PD-MCI patients from normal
controls and PDD patients already exist. Other biomarkers
can be investigated in plasma, too. Indeed, plasma α-synuclein
levels are reported as significantly higher in PD patients with
dementia than in PD patients with MCI or normal cognition, by
suggesting that α-synuclein may assist clinicians in identifying
progression towards degeneration (Lin et al., 2017). Moreover,
also in the case of PD-MCI, it should be useful for prognostic
and therapeutic purposes to approach a diagnostic algorithm
orienting clinical judgment as that built for ‘‘traditional’’ MCI
(Petersen et al., 2014).
Motor phenotypes and their neuropsychological patterns
in PD-MCI patients (i.e., tremor-dominant, akinetic-rigid, and
mixed profile) should be investigated longitudinally, in order
to detect PD-MCI patients at higher risk, given that tremor-
dominant phenotype tends to progress into akinetic-rigid
phenotype in the course of PD progression (Wojtala et al., 2019).
Further research should improve therapeutic trials for
PD-MCI examining the effects of pharmacological agents
affecting neurotransmission to better investigate the correlation
between α-synuclein and cognitive decline of PD-MCI patients,
implement CT protocols by large randomized controlled trials
with longitudinal follow-ups even in association with tDCS,
and explore the role of combined physical exercise and
CT interventions.
There is now an increasing body of clinical evidence
suggesting that physical exercise is a beneficial, cost-effective, and
low-risk intervention for patients with PD. According to Fayyaz
et al. (2018), optimally prescribed physical exercise programs
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may modulate neurophysiological processes possibly slowing
down PD symptoms, especially for patients with moderate
cognitive and physical impairment. PA has been shown to
attenuate dopaminergic neuron damage and reduce cellular
inflammation and oxidative stress (Nardello et al., 2017), thus
playing a pivotal role in non-pharmacological interventions.
Regular and moderate PA induces positive modification on
cortisol level, endothelium function, and reduced inflammation.
Indeed, endothelium-dependent flow-mediated dilation has been
observed to be lower in sedentary older subjects as compared
with older athletes (Franzoni et al., 2005). PA is a good method
even in pathological conditions, as shown by Donia et al. (2019),
reporting that acute exercise can positively induce changes in
inflammation with reduction of TNF-α.
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